medigraphic.com
ISSN 1561-2996 (Electronic)
ISSN 0864-0289 (Print)

2012, Number 2

<< Back Next >>

Rev Cubana Hematol Inmunol Hemoter 2012; 28 (2)

Therapeutic plasmapheresis. Two-year analysis at the Institute of Hematology and Immunology

Fernández-Delgado N, Forrellat-Barrios M, González-Suárez T, Salgado-Arocena O

Language: Spanish
References: 41
Page: 151-168
PDF size: 99.70 Kb.


ABSTRACT

Therapeutic plasma exchange is an extracorporeal procedure in which, after removing the whole blood, plasma is separated from other cellular components with the aim of reducing or eliminating pathological substances involved in the pathophysiology of the disease. Today, apheresis procedure is the most frequently used in clinical medicine. In this paper, we mention fundamental advances in their indications, methods and replacement solutions. We evaluate indications of plasmapheresis, which were performed at the Institute of Hematology and Immunology from January 2009 to December 2010. There were evaluated 295 plasmapheresis performed in 35 patients with 9 diseases or conditions associated with them. 60 % matched Class I of the American Association of Apheresis (ASFA) and this procedure was effective in 88.6 % of cases. The exchange volume ranged from 750 to 2 400 mL and the most common replacement solution was saline solution, followed by fresh frozen plasma and albumin. 4.06 % of these patients had some adverse reactions related to the proceeding, but these were mild and easily controlled. Plasmapheresis is a procedure with enormous therapeutic benefits when used in diseases, which have proven its effectiveness.


REFERENCES

  1. Pineda AA. Therapeutic Apheresis in the year 2001. Haematologica. 2001;86(1):103-6.

  2. Medina-Macias M. Aféresis terapéutica. Recambio plasmático. Citaféresis. Rev Med Inst Mex Seguro Soc. 2005;43(1):47-52.

  3. Quintana GS. Recolección de multicomponentes por aféresis. Gac Med Mex. 2003;S5151-4.

  4. Manual Técnico. Asociación Argentina de Hemoterapia e Inmunohematología & American Association of Blood Banks. 13ra ed. Buenos Aires: Asociación Argentina de Hemoterapia e Inmunohematología; 2001. p. 134-49. ISBN 987-96497-1-0.

  5. Ballester-Santovenia JM. Aféresis terapéutica. En ABC de la Medicina Transfusional: Guías clínicas. La Habana: OPS - MINSAP;2006. p. 86-92.

  6. Restrepo CA, Márquez E, Sanz MF. Plasmaféresis terapéutica, tipos, técnicas e indicaciones en medicina interna. Acta Méd Col Med Int. 2009;34(1):23-32.

  7. Hughes RAC, Wijdicks EFM, Barohn R, Benson E, Cornblath DR, Hahn AF, et al. Practice parameter: Immunotherapy for Guillain-Barre syndrome. Report of the quality standards subcommittee of the American Academy of Neurology. Neurology. 2003;61:736-40.

  8. Fernández-Lomana FA. Aféresis terapéutica: Plasmaféresis, inmunoadsorción, doble filtración y plasmadsorción. Aspectos biofísicos, clínicos y prácticos. Tesis Doctoral. Madrid: Universidad Complutense;1996.

  9. Vamvakas EC, Pineda AA. Selective extraction of plasma constituents. En: McLeod BC, Price TH, Weinstein R, eds. Apheresis: Principles and practice. 2nd ed. Bethesda:AABB; 2003. p. 437-76.

  10. Bravo-Lindoro A, Méndez-Jácome DL, Medina-Macías ML, Béjar Ramírez Y, Sánchez- Guerrero S. Aféresis terapéutica. Rev Med Inst Mex Seguro Soc. 2006;44(2):77-80.

  11. Council on Scientific Affairs. Current status of therapeutic plasmapheresis and related techniques. JAMA. 1985;8:189-94.

  12. Strauss RG, Ciavarella D, Gilcher RO, Kasprisin DO, Kiprov DD, Klein HG, et al. Clinical applications of therapeutic hemapheresis: an overview of current management. J Clin Apheresis. 1993;8:189-94.

  13. McLeod BC. Introduction to the third special issue: Clinical applications of therapeutic apheresis. J Clin Apher. 2000;15:1-5.

  14. Smith JW, Weinstein R, Hillyer KL. Therapeutic apheresis: a summary of current indication categories endorsed by the AABB and the American Society for Apheresis. Transfusion. 2003;43:820-22.

  15. Szczepiorkowski ZM, Bandarenko N, Kim HC, Linewnberger ML, Marques MB, Sarode R, et al. Guidelines on the use of therapeutic apheresis in clinical practice- evidence based approach from the Clinical Applications Committee of the American Society for Apheresis. J Clin Apher. 2007 Jun;22(3):106-75.

  16. Szczepiorkowski ZM, Shaz BH, Bandarenko N,Winters J. The new approach to assignment of ASFA Categories-introduction to the Fouurth special issue: Clinical applications of therapeutic apheresis. J Clin Apheresis. 2007;22:96-105. DOI 10.1002jca.20134.

  17. Mazzara R. Recambios plasmáticos. Soluciones de reposición. XLIII Reunión Nacional de la AEHH y XVII Congreso Nacional de la SETH. Simposios. Haematologica. 2001;86(1):109-13.

  18. Bencomo A, Alfonso ME, Alfonso Y, González R, Fernández J, Ballester A. Frecuencia de los grupos sanguíneos A1, A2, Ael, B y O en donantes de sangre. Rev Cubana Hematol Inmunol Hemoter. 1997;13(2):124-31.

  19. Bencomo A, Alfonso Y, Alfonso ME, González R, Martínez M. Frecuencia de los grupos sanguíneos ABO y Rh en donantes de sangre cubanos. Rev Argentina de Transfusión. 1997;23(1):20-1.

  20. Tazi I, Mesini F, Majd A, Benchemsi N. Therapeutic plasma exchange in Casablanca. Transfus Apher Sci. 2008;39:45-8.

  21. Alfonso-Valdés ME, Bencomo-Hernández A, Macías-Abraham C, Ballester-Santovenia JM. Desarrollo de la Medicina Transfusional en el Instituto de Hematología e Inmunología en el período 1996-2010. Rev Cubana Hematol Inmunol Hemoter. 2011;27(1):128-38 [serie en internet]. 2011 Abr [citado 2011 mayo 17] ; 27(1): Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0864-02892011000100011&lng=es

  22. Stegmayr B, Putak J, Wikstrom B. World apheresis registry report. Transfus Apher Sci. 2007;36:13- 6.

  23. Almagro-Vázquez D. Algunas consideraciones acerca de la púrpura trombocitopénica trombótica. Rev Cubana Hematol Inmunol Hemoter. [serie en internet]. 2007 Abr [citado 2011 mayo 17];23(1): Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0864-02892007000100002&lng=es

  24. Toffelmire EB, Clark WF, Cordy PE, Linton AL, Lohmann RC. Plasma exchange in thrombotic thrombocytopenic purpura. Can Med Assoc J. 1984;131(1):1371- 6.

  25. Altuntas F, Aydogdu I, Kabukcu S, Kocyigit I, Cikim K, Sari I, et al. Therapheutic plasma exchange for the treatment of thrombotic thrombocytopenic purpura: a retrospective multicenter study. Transfus Apher Sci. 2007;36:57-67.

  26. Li Z, Teng B, Luo J, Zhao J. Clinical application of therapeutic plasma exchange in the Three Gorges Area. Transfus Apher Sci. 2010;43:305-8.

  27. Ghobrial IM, Stewart AK. ASH evidence-based guidelines: what is the role of maintenance therapy in the treatment of multiple myeloma? Hematology. 2009:587-9.

  28. Shahidi S, Memarzadeh M, Kamali M, Naini AE. Trend of indications for therapeutic plasma exchange at an Iranian university hospital. Transfus Apher Sci. 2011;44:119-22.

  29. Rock GA, Herbert CA. Canadian Apheresis Group. Therapeutic apheresis in Canada. J Clin Apheresis. 1992;7:47-8.

  30. Korach JM, Bussel A, Gajdos P. The national survey of plasma exchange and therapeutic apheresis in France. Transfus Sci 1995;16:363-70.

  31. Carbajal-Ramírez A, Castañón-González JA, Talavera JO, De la Torre-Nieto ML, León-Gutiérrez MA. Plasmaféresis en el síndrome de Guillain-Barre. Gac Med Mex. 2002;138(6):527-31.

  32. Korinthenberg R, Monting JS. Natural history and treatment effects in Guillain-Barré syndrome: a multicentre study. Archives of Disease in Childhood. 1996;74:281-7.

  33. Osterman PO, Lundemo G, Pirskanen R, Fagius J, Pihlstedt P, Sidén A, et al. Beneficial effects of plasma Exchange in acute inflammatory polyradiculopathy. Lancet. 1984;2:1296-9.

  34. Mckahann GM, Griffin JW, Cornblath DR, and the Guillain Barre Syndrome Study Group. Plasmapheresis and Guillain Barré syndrome: analysis of prognostic factors and the effect of plasmapheresis. Ann Neurol. 1988;23:347-53.

  35. Fernández-Ortega JF, de Rojas-Román JP, Núnez-Castain MJ, Miralles-Martin E, Bravo-Utrera M. Sindrome de Guillain-Barre en Unidad de Cuidados Intensivos. Rev Neurol. 2001;33(4):318-24.

  36. Szczepiorkowski ZM, Winters JL, Bandarenko N, Kim HC, Linewnberger ML, Marques MB, et al. Guidelines on the use of therapeutic apheresis in clinical practice- evidence based approach from the Apheresis Applications Committee of the American Society for Apheresis. J Clin Apheresis. 2010;25:83- 177.

  37. Alfonso-Valdés ME. Sustitutos de la sangre. Rev Cubana Hematol Inmunol Hemoter [serie en internet]. 2001;17: 90-97. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0864-02892001000200002&lng=es

  38. Lasky LC, Finnerty EP, Genis L, Polesky HF. Protein and colloid osmotic pressure changes with albumin and &or saline replacement during plasma exchange. Transfusion. 1984;24:256-9.

  39. Mielke CH, Mielke MR. Technical and therapeutic applications of plasma exchange. Prog Clin Biol Res. 1981;65:123-45.

  40. Reimann PM, Mason PD. Review articles. Plasmapheresis: technique and complications. Intensive Cre Med. 1990;16:3-10.

  41. Medina-Macías ML, Béjar-Ramírez YL, Lordméndez-Jácome D. Aféresis terapéutica en pediatría. Recambio plasmático terapéutico. Citaféresis. Rev Mex Med Tran. 2008;1(1):23-30.




2020     |     www.medigraphic.com